New cell-based system can screen drug candidates for cardiac toxicity long before they leave lab

December 17, 2012

A new stem cell-derived system for screening experimental drugs for cardiotoxicity could identify dangerous side effects early in the development process, thereby potentially saving time, lives and money, according to Evan F. Cromwell, PhD, of Molecular Devices, LLC, Sunnyvale, CA, in a presentation at the American Society for Cell Biology's Annual Meeting, Dec 17 in San Francisco.

Vioxx is probably the most notorious example of a blockbuster drug removed from the market after FDA approval because of adverse cardiac side effects, Dr. Cromwell explained, but it was not the only drug to fail because of unexpected negative effects on the heart.

Cardiotoxicity remains one of the primary reasons new drugs wash out in preclinical or even full clinical trials, he said. There is often a huge cost for these failures, both to the pharmaceutical companies whose long-term investments can be wiped out in a single study and to consumers who face the risk of unintended harm.

Currently cardiotoxicity is detected using electrophysiology-based assays for interactions of compounds with potassium ion channels. However, available assays are not effective at assessing potential adverse interactions with other biochemical or contractile processes.

The need for better cardiotoxicity assays more predictive of myocardial performance led Dr. Cromwell, Oksana Sirenko, PhD, and colleagues at the California biotech, Molecular Devices, to develop an in vitro system that employs stem cell-derived cardiomyocytes to screen for potential adverse cardiac effects.

Stem cell-derived cardiomyocytes are especially suitable for an in vitro system, Dr. Cromwell explains, because they express ion channels vital for the cardiomyocytes' function and demonstrate spontaneous mechanical and electrical activity similar to that of native cardiac cells. When these cultured cardiomyocytes form a confluent layer and reach sufficient maturity, they begin to contract spontaneously. The team then employs a fast kinetic fluorescence imaging method to monitor fluctuations in intracellular calcium ion (Ca2+) levels during contractions. This provides a direct assessment of Ca2+ handling with surrogate assessments of electrophysiological activity in the muscle cell membrane and beat rate.

Phenotypic deviations from normal contractions that can be measured in the improved assay include beat rate, peak width and pattern irregularities. This multiparametric characterization of a compound's perturbation of cardiomyocyte contractions can also yield insights into mechanisms of action (MOA).

Dr. Cromwell reports, "We have characterized numerous pharmacological compounds and detected concentration-dependent modulation of beating rate and atypical patterns consistent with their MOA." This assay shows great promise to exclude preclinical candidates that have cardiotoxicity or other cardio safety issues, according to Dr. Cromwell.
-end-
CONTACT

Evan F. Cromwell, PhD
Molecular Devices, LLC
408-747-3523
evan.cromwell@moldev.com

John Fleischman
American Society for Cell Biology
jfleischman@ascb.org
513-706-0212

Cathy Yarbrough
Cyarbrough@ascb.org
858-243-1814

AUTHOR PRESENTS

"Predictive assays for high throughput assessment of cardiac toxicity and drug safety," Sunday, Dec.16, 2012, 2- 3:30 pm, Session: New Technologies for Cell Biology I, presentation: 938, poster: B1496

American Society for Cell Biology

Related Cardiomyocytes Articles from Brightsurf:

CNIC researchers discover a cell-cleaning system that keeps hearts healthy
The study published in Cell shows that macrophages, a type of immune cell, help cardiac cells to get rid of their waste material, and that this maintains the metabolic and contractile properties of the heart.

Ageing heart cells offer clues to susceptibility of older people to severe COVID-19
Genes that play an important role in allowing SARS-CoV-2 to invade heart cells become more active with age, according to research published today in the Journal of Molecular and Cellular Cardiology.

Direct reprogramming: Defying the contemporary limitations in cardiac regeneration
Repair and regeneration of myocardium are the best possible therapy for the end-stage heart failure patients because the current therapies that can help restore the lost cardiomyocytes are limited to heart transplantation only.

Image analysis technique provides better understanding of heart cell defects
Many patients with heart disease face limited treatment options. Fortunately, stem cell biology has enabled researchers to produce large numbers of cardiomyocytes, which may be used in drug screens and cell-based therapies.

Changing what heart cells eat could help them regenerate
Switching what the powerhouses of heart cells consume for energy could help the heart regenerate when cells die.

Heart attack modeled with human stem cells
A model of ischemic heart disease was developed using human induced pluripotent stem cells (hiPSC).

A kinase identified as possible target to treat heart failure
An unexplored kinase in heart muscle cells may be a good target to treat heart failure, a disease that is only incrementally delayed by existing therapies.

Special cells contribute to regenerate the heart in Zebrafish
It is already known that zebrafish can flexibly regenerate their hearts after injury.

Platform for lab-grown heart cells lets researchers examine functional effects of drugs
The human heart's energy needs and functions are difficult to reproduce in other animals; one new system looks to circumvent these issues and provide a functional view of how different treatments can help ailing cells in the heart following oxygen and nutrient deprivations.

A simple method to improve heart-attack repair using stem cell-derived heart muscle cells
The heart cannot regenerate muscle after a heart attack, and this can lead to lethal heart failure.

Read More: Cardiomyocytes News and Cardiomyocytes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.